CN116322643A - 用环糊精治疗胆固醇结晶栓塞的方法 - Google Patents

用环糊精治疗胆固醇结晶栓塞的方法 Download PDF

Info

Publication number
CN116322643A
CN116322643A CN202180053198.8A CN202180053198A CN116322643A CN 116322643 A CN116322643 A CN 116322643A CN 202180053198 A CN202180053198 A CN 202180053198A CN 116322643 A CN116322643 A CN 116322643A
Authority
CN
China
Prior art keywords
cholesterol crystals
cyclodextrin
individual
amount
hydroxypropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180053198.8A
Other languages
English (en)
Chinese (zh)
Inventor
D·克尔温
J·卡姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beren Treatment Public Welfare Co
Original Assignee
Beren Treatment Public Welfare Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beren Treatment Public Welfare Co filed Critical Beren Treatment Public Welfare Co
Publication of CN116322643A publication Critical patent/CN116322643A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
CN202180053198.8A 2020-08-27 2021-08-27 用环糊精治疗胆固醇结晶栓塞的方法 Pending CN116322643A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063071222P 2020-08-27 2020-08-27
US63/071,222 2020-08-27
PCT/US2021/048072 WO2022047241A1 (en) 2020-08-27 2021-08-27 Methods for the treatment of cholesterol crystal embolization with cyclodextrins

Publications (1)

Publication Number Publication Date
CN116322643A true CN116322643A (zh) 2023-06-23

Family

ID=80353289

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180053198.8A Pending CN116322643A (zh) 2020-08-27 2021-08-27 用环糊精治疗胆固醇结晶栓塞的方法

Country Status (11)

Country Link
US (1) US20230330133A1 (cg-RX-API-DMAC10.html)
EP (1) EP4203972A4 (cg-RX-API-DMAC10.html)
JP (1) JP7835735B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230096975A (cg-RX-API-DMAC10.html)
CN (1) CN116322643A (cg-RX-API-DMAC10.html)
AU (1) AU2021333902A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023003455A2 (cg-RX-API-DMAC10.html)
CA (1) CA3190563A1 (cg-RX-API-DMAC10.html)
IL (1) IL300806A (cg-RX-API-DMAC10.html)
MX (1) MX2023002419A (cg-RX-API-DMAC10.html)
WO (1) WO2022047241A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016276774A1 (en) 2015-06-10 2018-01-18 Vtesse, Inc. Hydroxypropyl beta-cyclodextrin compositions and methods
EP4294403A4 (en) * 2021-02-18 2024-12-11 Beren Therapeutics P.B.C. METHODS OF TREATMENT OF HETEROZYGOUS AND HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA WITH CYCLODEXTRINS
JP2025506676A (ja) 2022-02-18 2025-03-13 ベレン セラピューティクス ピー．ビー．シー． ヒドロキシプロピル－ベータ－シクロデキストリンの組成物及びその精製方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4877778A (en) * 1987-07-01 1989-10-31 The Children's Medical Center Corporation Method of enhancing lipophile transport using cyclodextrin derivatives
WO2013155485A2 (en) * 2012-04-13 2013-10-17 Alessia Fornoni Method of using cyclodextrin

Also Published As

Publication number Publication date
JP7835735B2 (ja) 2026-03-25
EP4203972A1 (en) 2023-07-05
BR112023003455A2 (pt) 2023-05-02
KR20230096975A (ko) 2023-06-30
AU2021333902A1 (en) 2023-03-16
EP4203972A4 (en) 2024-07-17
MX2023002419A (es) 2023-07-11
US20230330133A1 (en) 2023-10-19
JP2023543133A (ja) 2023-10-13
WO2022047241A1 (en) 2022-03-03
CA3190563A1 (en) 2022-03-03
IL300806A (en) 2023-04-01

Similar Documents

Publication Publication Date Title
AU2022204217B2 (en) Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide
JP7835735B2 (ja) シクロデキストリンによるコレステロール結晶塞栓症の治療方法
CN108366963A (zh) 包含丹曲林的水性组合物
CN116635007A (zh) 用环糊精预防胆固醇结晶栓塞的方法
US20230375576A1 (en) Methods for the treatment of familial heterozygous and homozygous hypercholesterolemia with cyclodextrins
US20230091966A1 (en) Methods for the treatment of cardiovascular disease with cyclodextrins
CA2516629A1 (en) Compositions and methods for preventing and treating endotoxin-related diseases and conditions
KR20240148426A (ko) 2-히드록시프로필-베타-사이클로덱스트린으로 고-트리글리세리드혈증을 치료
HK40084620A (en) Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination